HOME> product


Sales marketing
Bioactivity Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC50 value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus[1][2][3].
Invitro Frentizole (500 ng/mL, 48 hours) is effective in inhibiting thymidine incorporation into DNA when adds to lymphocyte cultures alongside mitogens, and significantly inhibits the response to concanavalin A by 58% in a dose-dependent manner in lymphocytes extracted from mice peritoneal cavity[1]. Frentizole (62.5 ng/mL) can effectively inhibit uridine incorporation and the inhibition of uridine incorporation is independent of the phytochemical used[1].
In Vivo Frentizole (8.2 or 79.9 mg/kg/day for young mice in animal feedings, 52 weeks) can extend the life span of NZB/NZW mice[2]. Animal Model:
Name Frentizole
CAS 26130-02-9
Formula C15H13N3O2S
Molar Mass 299.35
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Meisel AD, et al. Effect of frentizole on mitogen-induced blastogenesis in human lymphocytes. J Immunopharmacol. 1979;1(4):483-95. [2]. Walker SE, et al. Prolonged lifespans in female NZB/NZW mice treated with the experimental immunoregulatory drug frentizole. Arthritis Rheum. 1982 Nov;25(11):1291-7. [3]. Yuli Xie, et al. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4657-60.

About Contact

© 2008-2024 PeptideDB SYSTEM All Rights Reserved